Redox Pharmaceutical Corporation announced the granting of a new United States patent on the use of CTC-96 (Doxovir™) for the Treatment of Psoriasis.

Redox Pharmaceutical Corporation has successfully completed Phase IB and Phase II Clinical Trials for Herpes Labialis (cold sores).

The Company has developed a body of patents covering

• anti-viral
• anti-inflammatory
• and anti-bacterial applications.

SEE ALSO

Our Company

Management and Board of Directors